LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Moderate Buy” by Analysts

LivaNova PLC (NASDAQ:LIVN) has received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $65.6250.

A number of analysts have recently issued reports on LIVN shares. Mizuho increased their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Robert W. Baird set a $75.00 price objective on LivaNova in a report on Tuesday, December 16th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th.

LivaNova Trading Up 1.4%

Shares of NASDAQ LIVN opened at $64.12 on Wednesday. LivaNova has a one year low of $32.48 and a one year high of $65.57. The firm has a market capitalization of $3.50 billion, a PE ratio of -16.03 and a beta of 0.97. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The business has a 50-day moving average price of $59.40 and a two-hundred day moving average price of $53.74.

Hedge Funds Weigh In On LivaNova

Hedge funds have recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership lifted its stake in LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the last quarter. Invesco Ltd. boosted its holdings in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after purchasing an additional 902,447 shares in the last quarter. Scopia Capital Management LP acquired a new position in LivaNova during the second quarter worth $36,657,000. Finally, Millennium Management LLC raised its holdings in LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after buying an additional 544,033 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.